The public health crisis of Covid-19 has not only led to the rapid expansion of virtual medical services, but also accelerated the use of decentralized clinical trials. Decentralized clinical trials are considered a way to increase and maintain clinical trial participation, reduce the time to recruit participants, and have additional advantages.
in medical city Invest in medical technologyA virtual conference scheduled for Tuesday, July 26 will focus on this and related topics such as artificial intelligence to support drug development, the future of digital medicine, and more.
To view the full agenda, click here.
To register for free, click here.
Because of the pandemic, going to a hospital — often the site of a clinical trial — is no longer an option, requiring a reimagining of how clinical trials are designed. But can virtual, decentralized or siteless clinical trials be as effective as traditional trials? What are the pros and cons of conducting such trials?
thread research CEO John Reites will moderate a discussion on the topic with speakers including:
We are also looking for startups to participate in our Pitch Perfect competition. The theme of this meeting: Reinventing clinical trials.
Among the many post-pandemic realities, one is the need to make clinical trials more decentralized. Startups in this category are developing products—including technologies and services—that can help transform field-based field clinical trials into pure clinical trials, or introduce more digital elements into the traditional clinical trial process.
applied to the field, click here.
For sponsorship inquiries, please contact our publisher Ken Montgomery: kmontgomery@medcitynews.com
picture: exdez, Getty Images
